

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization  
International Bureau**



(43) International Publication Date  
11 January 2001 (11.01.2001)

PCT

**(10) International Publication Number  
WO 01/02007 A1**

(51) International Patent Classification<sup>7</sup>: A61K 39/00, (74) Agent: FRANCIS, Carol, L.; Bozicevic, Field & Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA 3902, 45/00, C07H 21/04

**(21) International Application Number:** PCT/US00/18229

(22) International Filing Date: 30 June 2000 (30.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/347,343 2 July 1999 (02.07.1999) US

(71) *Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200 (US).*

(72) Inventors; and  
(75) Inventors/Applicants (*for US only*): RAZ, Eyal [US/US]; 13658 Mango Drive, Del Mar, CA 92014 (US). KOBAYASHI, Hiroko [JP/JP]; 38, Maruraki Watari, Fukushima 960-8141 (JP).

(74) Agent: FRANCIS, Carol, L.; Bozicevic, Field & Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA 94025 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *With international search report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR ENHANCING AN IMMUNE RESPONSE

**(57) Abstract:** Disclosed is a method for enhancing an immune response to a substance, such as an antigen or microbial pathogen. The immune response can be, for example, production of IgG2 antibodies. The method comprises administering an immunostimulatory nucleotide sequence (ISS) to a subject at least one hour prior to exposure to the substance by the subject. The subject may be exposed to the substance either naturally, as with an environmental pathogen, or by administration, as with a known antigen. The method can be used for protecting or immunizing a subject against an antigen or pathogen, providing more effective immunization than if the ISS were co-administered with the substance. The method can be used prophylactically or therapeutically. In preferred embodiments, the ISS comprises a CG,p(GC) or p(IC)DNA or RNA nucleotide sequence. Of these, a CG containing nucleotide sequence is preferred. The ISS can further comprise a pG nucleotide sequence. Examples of an ISS include sequences comprising 5'-rcggg-3', 5'-rccgyy-3', 5'-rcggyyeg-3' or 5'-rycggyegc-3'. The ISS is preferably administered between about 6 hours and about 6 weeks prior to exposure to the substance, and more preferably between about 1 day and about 4 weeks prior. Most preferably, the ISS is administered between about 3 days and about 8 days prior to exposure to the substance. The ISS can be administered via a mucosal or systemic route. The substance can be an antigen or pathogen associated with an infectious disease, an allergen or a cancer.

METHOD FOR ENHANCING AN IMMUNE RESPONSE

- This application is related to pending United States patent applications having the serial numbers 09/167,039, filed October 5, 1998, and 09/235,742, filed January 20, 1999, the latter of which is a continuing prosecution application based on 08/927,120, filed September 5, 5 1997. The entire contents of each of these related applications are hereby incorporated by reference into this application. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention pertains.
- 10 This invention was made with Government support under Grant No. AI40682, awarded by the National Institutes of Health. The government has certain rights in this invention.

TECHNICAL FIELD OF THE INVENTION

The invention relates to a method for enhancing an immune response by administering an immunostimulatory nucleotide sequence prior to antigen exposure. More particularly, the 15 method is suited for enhancing antibody production, IFN $\gamma$  release, CTL activity and Th1-related effects in response to antigen administration.

BACKGROUND OF THE INVENTION

Adjuvants are typically administered in conjunction with antigen in vaccination protocols. Adjuvants serve to amplify or modulate the immune response to a co-delivered antigen. 20 Currently, few adjuvants (e.g., alum and MF59) have been approved for use in human vaccination.

Immunostimulatory DNA sequences (ISS) delivered in conjunction with an antigen activate innate immunity and bias the adaptive immune response toward Th1 differentiation. ISS have been used as an adjuvant to amplify the immune response to a co-delivered antigen. See, for 25 example, WO 98/16247, and United States Patents No. 5,736,524 and No. 5,780,448.

There remains a need for optimization of the nature and efficacy of vaccination and immunotherapeutic protocols.

SUMMARY OF THE INVENTION

The invention provides a method for enhancing an immune response to a substance, such as an antigen administered to a subject, or a pathogen to which the subject is exposed. The method can be used to modulate the magnitude, the duration, and the nature of the immune response  
5 to subsequent exposure to a substance. The method comprises administering an immunostimulatory nucleotide sequence (ISS) to the subject at least one hour prior to exposure to the substance by the subject. This "pre-priming" of the subject with ISS prior to antigen administration or pathogen exposure results in amplification of the Th1 immune response to the substance as compared to co-administration of ISS and antigen. Pre-priming  
10 with ISS also shifts the nature of the immune response from a Th2 type response to a Th1 type response.

Examples of an immune response that can be enhanced by the method of the invention include, but are not limited to, activation of innate immunity (e.g., macrophages, natural killer (NK) cells), a Th1 response, a cytotoxic T lymphocyte (CTL) response, and production of an  
15 antibody. The antibody response is preferably increased production of antibodies of the IgG2a subclass. The method can be used for immunizing a subject against an antigen, and provides more effective immunization than if the ISS were co-administered with the antigen. The method can be used prophylactically or therapeutically.

In preferred embodiments, the ISS comprises a CG, p(GC) or p(IC) DNA or RNA nucleotide sequence. Of these, a CG containing nucleotide sequence is preferred. Preferably, the ISS further comprises a pG nucleotide sequence. Examples of an ISS include, but are not limited to, sequences comprising 5'-rrcgyy-3' (SEQ ID NO: 1), such as AACGTT, AGCGTC, AGCGTT, GACGTT, GGCGTT, AACGTC, and AGCGTC (SEQ ID NOs: 5-11, respectively), 5'-rycgyy-3' (SEQ ID NO: 2) such as GTCGTT (SEQ ID NO: 24), 5'-rrcgyycg-  
25 3' (SEQ ID NO: 3), or 5'-rycgyycg-3' (SEQ ID NO: 4).

The ISS is preferably administered between about 6 hours and about 6 weeks prior to antigen administration, and more preferably between about 1 day and about 4 weeks prior to antigen administration. Most preferably, the ISS is administered between about 3 days and about 8 days prior to antigen administration. In a preferred embodiment of the method, the ISS is

administered via a systemic route such as a dermal or intramuscular route, or via a mucosal route such as an intranasal, ophthalmic, intrarectal, intravaginal or intratracheal route.

Because pre-priming activates innate immunity, the method of the invention can be used to protect against subsequent infection by a pathogen, such as a viral, bacterial, parasitic or other

- 5 infectious agent. Preferably, the substance is a pathogen or an antigen associated with an infectious disease, an allergen or a cancer. Examples of infectious disease include, but are not limited to, viral, bacterial, mycobacterial and parasitic disease:

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of the ISS pre-priming and  $\beta$ -gal immunization protocol  
10 described in the examples. Mice received a single i.d. or i.n. injection with ISS (50  $\mu$ g) either the specified days before or with  $\beta$ -gal (50  $\mu$ g) immunization via the same route (Day 0).

Control mice received  $\beta$ -gal immunization without ISS. Serial bleeds occurred after  $\beta$ -gal immunization, and mice were sacrificed during week 7 for determination of splenocyte cytokine and CTL responses. "i.d." refers to intradermal delivery; and "i.n." to intranasal

- 15 delivery.

Figure 2A is graph showing time course of IgG2a production after i.d. ISS pre-priming and  $\beta$ -gal immunization. Mice received either no ISS (open squares), ISS on day 0 (open circles), day -3 (closed diamonds), day -7 (closed circles), day -14 (closed squares), or day -28

- (closed triangles) relative to  $\beta$ -gal. Mice were bled at serial time points to establish the kinetics  
20 of IgG2a production. Results represent mean values for 4 mice per group and error bars reflect standard errors of the means. Results are representative of 3 similar and independent experiments.

Figure 2B is graph showing serum IgG2a after i.d. ISS pre-priming and  $\beta$ -gal immunization at 7 weeks post immunization. The open diamond represents data for mice receiving  $\beta$ -gal alone,

- 25 and the closed circles represent data for mice receiving ISS at the indicated day relative to  $\beta$ -gal administration. Results represent mean values for 4 mice per group and error bars reflect standard errors of the means. Results are representative of 3 similar and independent experiments. Mice receiving ISS up to 14 days prior to  $\beta$ -gal demonstrated an improved IgG2a response when compared to mice immunized with  $\beta$ -gal alone ( $\dagger$ ;  $p \leq 0.05$ ). Mice

receiving ISS 7 days before  $\beta$ -gal immunization had a significantly improved IgG2a response when compared to mice co-administered ISS with  $\beta$ -gal ( $\star; p \leq 0.05$ ).

Figure 2C is graph showing serum IgG1 after i.d. ISS pre-priming and  $\beta$ -gal immunization at 7 weeks post immunization. Results represent mean values for 4 mice per group and error bars reflect standard errors of the means. Results are representative of 3 similar and independent experiments.

Figure 3A is a bar graph showing the splenocyte IFN $\gamma$  response after i.d. ISS pre-priming and  $\beta$ -gal immunization. Results represent the mean for 4 mice in each group and similar results were obtained in 2 other independent experiments. Error bars reflect standard errors of the means. Mice receiving ISS up to 14 days prior to  $\beta$ -gal demonstrated an improved IFN $\gamma$  response when compared to mice immunized with  $\beta$ -gal alone ( $\dagger; p \leq 0.05$ ). Delivery of ISS from 3-7 days before  $\beta$ -gal led to an improved IFN $\gamma$  response when compared to mice receiving ISS/ $\beta$ -gal co-immunization ( $\star; p \leq 0.05$ ).

Figure 3B is a graph showing the splenocyte CTL response after i.d. ISS pre-priming and  $\beta$ -gal immunization. Mice received either no ISS (open squares), ISS on day 0 (open circles), day -3 (closed diamonds), day -7 (closed circles), day -14 (closed squares), or day -28 (closed triangles) relative to  $\beta$ -gal. Results represent the mean for 4 mice in each group and similar results were obtained in 2 other independent experiments. Error bars reflect standard errors of the means.

Figure 3C is a plot showing a comparison of CTL response at an effector:target ratio of 25:1. The open diamond represents data for mice receiving  $\beta$ -gal alone, and the closed circles represent data for mice receiving ISS at the indicated day relative to  $\beta$ -gal administration. Mice receiving ISS up to 14 days prior to  $\beta$ -gal demonstrated an improved CTL response when compared to mice immunized with  $\beta$ -gal alone ( $\dagger; p \leq 0.05$ ).

Figure 4 shows splenocyte cytokine mRNA expression. Mice were i.d. injected with 50  $\mu$ g of ISS on day 0. Control mice received either LPS (50  $\mu$ g) or nothing. At serial time points after injection, mice were sacrificed, splenocytes were isolated, and subjected to RT-PCR. PCR products were visualized by electrophoresis on 2% agarose gels and staining with ethidium bromide.

Figure 5A is a bar graph showing splenocyte IFN $\gamma$  response after i.n. ISS pre-priming and  $\beta$ -gal immunization. Results represent the mean for 4 mice in each group and similar results were obtained in 2 other independent experiments. Error bars reflect standard errors of the means. Mice receiving ISS up to 7 days prior to  $\beta$ -gal demonstrated an improved IFN $\gamma$  response when compared to mice immunized with  $\beta$ -gal alone ( $\dagger; p \leq 0.05$ ). Delivery of ISS from 1-3 days before  $\beta$ -gal led to an improved IFN $\gamma$  response when compared to mice receiving ISS/ $\beta$ -gal co-immunization ( $\star; p \leq 0.05$ ).

Figure 5B is a graph showing splenocyte CTL response after i.n. ISS pre-priming and  $\beta$ -gal immunization. Mice received either no ISS (open squares), ISS on day 0 (open circles), or day -1 (closed triangles), day -3 (closed diamonds), day -7 (closed circles), or day -14 (closed squares) relative to  $\beta$ -gal. Results represent the mean for 4 mice in each group and similar results were obtained in 2 other independent experiments. Error bars reflect standard errors of the means. Mice receiving ISS up to 7 days prior to  $\beta$ -gal demonstrated statistically improved CTL responses at effector:target ratios of 5:1 and 25:1 when compared to mice immunized with  $\beta$ -gal alone ( $p \leq 0.05$ ).

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an unconventional approach to amplifying the immune response *in vivo*. This approach provides a practical tool to amplify the immune response to subsequent antigen exposure, to activate innate immunity, to generate CTL activity and to bias the subsequent immune response toward a Th1 type of response. The invention is based on the discovery that pre-priming a subject by dissociating ISS delivery from antigen delivery significantly amplifies the immune response to antigen. This pre-priming effect is applicable to both systemic and mucosal immunization, and can be used for protection against antigens as well as against pathogens. The invention additionally provides information about the kinetics of the pre-priming effect and the optimal timing for ISS delivery for both systemic and mucosal applications.

The invention is also based on the discovery that ISS administration activates innate immunity as evidenced by increased serum levels of IFN $\gamma$  and IL-12, which activate macrophages and natural killer (NK) cells, respectively. The method of the invention can thus be used for broad protection against subsequently encountered pathogens as well as against subsequently

administered antigens. The combination of information about activation of innate immunity and the time course of ISS-induced enhancement of immune responses enables an effective strategy for protection against a broad range of substances.

Definitions

- 5 All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.

As used herein, "immunostimulatory nucleotide sequence" or "ISS" means a polynucleotide that includes, or consists of, at least one immunostimulatory oligonucleotide (ISS-ODN)

- 10 moiety. The ISS moiety is a single-or double-stranded DNA or RNA oligonucleotide having at least six nucleotide bases that may include, or consist of, a modified oligonucleotide or a sequence of modified nucleosides. The ISS moieties comprise, or may be flanked by, a CG containing nucleotide sequence or a p(IC) nucleotide sequence, which may be palindromic.

- 15 As used herein, "polynucleotide" refers to DNA or RNA and can include sense and antisense strands as appropriate to the goals of the therapy practiced according to the invention.  
Polynucleotide in this context includes oligonucleotides.

- As used herein, "subject" refers to the recipient of the therapy to be practiced according to the invention. The subject can be any vertebrate, but will preferably be a mammal. If a mammal, the subject will preferably be a human, but may also be a domestic livestock, laboratory  
20 subject or pet animal.

As used herein, "substance" refers to any substance to which an immune response may be directed, and includes antigens and pathogens.

As used herein, "exposure" to a substance includes both natural, environmental exposure to the substance as well as administration of the substance to a subject.

- 25 As used herein, enhancing "innate immunity" includes enhancing activation of macrophages, NK cells, antigen presenting cells (APCs), and other elements known to be involved in protection against subsequent exposure to microbial pathogens. Enhancement of innate

immunity can be determined using conventional assays for activation of these elements, including but not limited to assays described in the examples set forth below.

As used herein, "enhancing a Th1 immune response" in a subject is evidenced by:

- (1) a reduction in levels of IL-4 or IL-5 measured before and after antigen challenge; 5 or detection of lower (or even absent) levels of IL-4 in a treated subject as compared to an antigen-primed, or primed and challenged, control;
- (2) an increase in levels of IL-12, IL-18 and/or IFN ( $\alpha$ ,  $\beta$  or  $\gamma$ ) before and after antigen challenge; or detection of higher levels of IL-12, IL-18 and/or IFN ( $\alpha$ ,  $\beta$  or  $\gamma$ ) in an ISS treated subject as compared to an antigen-primed or, primed and challenged, 10 control;
- (3) production of IgG2a antibody or its human analog in a treated subject;
- (4) a reduction in levels of antigen-specific IgE as measured before and after antigen challenge; or detection of lower (or even absent) levels of antigen-specific IgE in an ISS treated subject as compared to an antigen-primed, or primed and challenged, control; and/or 15
- (5) induction of a cytotoxic T lymphocyte ("CTL") response in a treated subject.

Exemplary methods for determining such values are described further in the Examples. The ISS of the invention provide relatively safe, effective means of stimulating a robust immune response in a vertebrate subject against any antigen.

20 **Methods**

The invention provides a method for enhancing an immune response. The method can be used to modulate the magnitude, the duration and/or the quality of the immune response to a subsequently administered antigen or to subsequent exposure to a substance such as a pathogen. In one embodiment, the method enhances the production of antibodies that 25 recognize the substance. Enhanced antibody production can be determined by detecting increased antibody levels in a subject or subjects pre-primed with ISS as compared to antibody levels in a subject or subject not receiving ISS prior to antigen administration. An example of

a suitable assay for determining enhanced antibody production is described below in Example 1. Enhanced antibody production can also include increasing the production of one class of antibody relative to production of another, less desirable class of antibody. For example, production of IgG2a antibodies can be enhanced while levels of IgE antibodies are reduced.

- 5 The immune response can also be enhanced by shifting the response from a Th2 to a Th1 type response. As used herein, "Th1/Th2 response(s)" refer to types 1 and 2, respectively, helper T lymphocyte (Th) mediated immune responses. Th2 responses include the allergy-associated IgE antibody class as well as elevated levels of IL-4 and IL-5 cytokines by Th2 lymphocytes. Soluble protein antigens tend to stimulate relatively strong Th2 responses. Th1 cells secrete  
10 IL-2, interferon-gamma (IFN $\gamma$ ) and tumor necrosis factor-beta (TNF $\beta$ ) (the latter two of which are involved in macrophage activation and delayed-type hypersensitivity in response to antigen stimulation or infection with a pathogen).

Accordingly, Th2 associated responses can be suppressed, thereby reducing the risk of prolonged allergic inflammation and antigen-induced anaphylaxis. The enhancement of Th1 15 associated responses is of particular value in responding to intracellular infections because cellular immunity is enhanced by activated Th1 (IFN $\gamma$ ) cells. In addition, administration of polynucleotides helps stimulate production of CTL, further enhancing the immune response.

The method of the invention can be used to modulate or enhance the immune response both prophylactically and therapeutically. Thus, the invention provides a method of immunizing a 20 subject as well as a method of immunotherapy.

The method of the invention comprises administering an ISS to a subject prior to exposure to the substance. This pre-priming is typically performed at least one hour prior to antigen administration or other exposure to a substance. The ISS is preferably administered between about 6 hours and about 6 weeks prior to antigen administration or other exposure to a 25 substance, and more preferably between about 1 day and about 4 weeks prior to antigen administration. Most preferably, the ISS is administered between about 3 days and about 8 days prior to antigen administration. The antigen or other substance can be introduced by conventional immunization techniques, or by natural exposure.

Preferably, the substance is an antigen or a pathogen associated with an infectious disease, an allergen or a cancer. Examples of infectious disease include, but are not limited to, viral, bacterial, mycobacterial and parasitic disease. Examples of allergens include, but are not limited to, plant pollens, dust mite proteins, animal dander, saliva and fungal spores. Examples 5 of cancer-associated antigens include, but are not limited to, live or irradiated tumor cells, tumor cell extracts and protein subunits of tumor antigens. The antigen can also be a sperm protein for use in contraception. In some embodiments, the antigen is an environmental antigen. Examples of environmental antigens include, but are not limited to, respiratory syncytial virus ("RSV"), flu viruses and cold viruses.

10 Structure and Preparation of ISS

The ISS of the invention includes an oligonucleotide, which can be a part of a larger nucleotide construct such as a plasmid or bacterial DNA. The term "polynucleotide" therefore includes oligonucleotides, modified oligonucleotides and oligonucleosides, alone or as part of a larger construct. The polynucleotide can be single-stranded DNA (ssDNA), double-stranded 15 DNA (dsDNA), single-stranded RNA (ssRNA) or double-stranded RNA (dsRNA). The ISS can include bacterial DNA, which provides ISS activity.

The polynucleotide portion can be linearly or circularly configured, or the oligonucleotide portion can contain both linear and circular segments. Modifications of oligonucleotides include, but are not limited to, modifications of the 3'OH or 5'OH group, modifications of the 20 nucleotide base, modifications of the sugar component, and modifications of the phosphate group.

The ISS can comprise ribonucleotides (containing ribose as the only or principal sugar component), deoxyribonucleotides (containing deoxyribose as the principal sugar component), or in accordance with the established state-of-the-art, modified sugars or sugar analogs may be 25 incorporated in the oligonucleotide of the present invention. Examples of a sugar moiety that can be used include, in addition to ribose and deoxyribose, pentose, deoxypentose, hexose, deoxyhexose, glucose, arabinose, xylose, lyxose, and a sugar "analog" cyclopentyl group. The sugar may be in pyranosyl or in a furanosyl form. In the modified oligonucleotides of the present invention, the sugar moiety is preferably the furanoside of ribose, deoxyribose,

arabinose or 2'-O-methylribose, and the sugar may be attached to the respective heterocyclic bases either in I or J anomeric configuration.

The phosphorous derivative (or modified phosphate group) that can be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention can be a

- 5 monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphoronthioate, phosphorodithioate or the like. The heterocyclic bases, or nucleic acid bases that are incorporated in the oligonucleotide base of the ISS can be the naturally occurring principal purine and pyrimidine bases, (namely uracil or thymine, cytosine, adenine and guanine, as mentioned above), as well as naturally occurring and synthetic modifications 10 of said principal bases. Those skilled in the art will recognize that a large number of "synthetic" non-natural nucleosides comprising various heterocyclic bases and various sugar moieties (and sugar analogs) are available, and that the ISS can include one or several heterocyclic bases other than the principal five base components of naturally occurring nucleic acids. Preferably, however, the heterocyclic base in the ISS is selected from uracil-5-yl, 15 cytosin-5-yl, adenin-7-yl, adenin-8-yl, guanin-7-yl, guanin-8-yl, 4-aminopyrrolo [2,3-d] pyrimidin-5-yl, 2-amino-4-oxopyrrolo [2,3-d] pyrimidin-5-yl, 2-amino-4-oxopyrrolo [2,3-d] pyrimidin-3-yl groups, where the purines are attached to the sugar moiety of the oligonucleotides via the 9-position, the pyrimidines via the 1-position, the pyrrolopyrimidines via the 7-position and the pyrazolopyrimidines via the 1-position.
- 20 Structurally, the root oligonucleotide of the ISS is a non-coding sequence that can include at least one unmethylated CpG motif. The relative position of any CpG sequence in ISS with immunostimulatory activity in certain mammalian species (e.g., rodents) is 5'-CG-3' (i.e., the C is in the 5' position with respect to the G in the 3' position).

- Some oligonucleotide ISS (ISS-ODN) are known. In such ISS-ODN, the CpG motif is flanked 25 by at least two purine nucleotides (e.g., GA or AA) and at least two pyrimidine nucleotides (5'-r-r-[C]-[G]-y-y-3'; SEQ ID NO: 1), or flanked by a purine and a pyrimidine 5' to the CG (5'-r-y-[C]-[G]-y-y-3'; SEQ ID NO: 2), wherein the pyrimidine 5' to the CG is preferably T. CpG motif-containing ISS-ODN are believed to stimulate B lymphocyte proliferation (see, e.g., Krieg, et al., Nature, 374:546-549, 1995).

The core hexamer structure of the foregoing ISS can be flanked upstream and/or downstream by any number or composition of nucleotides or nucleosides. However, ISS are at least 6 bases in length, and preferably are between 6 and 200 bases in length, to enhance uptake of the ISS into target tissues. Those of ordinary skill in the art will be familiar with, or can readily identify, reported nucleotide sequences of known ISS-ODN for reference in preparing ISS.

5 For ease of reference in this regard, the following sources are especially helpful: Yamamoto, et al., *Microbiol. Immunol.*, 36:983 (1992); Ballas, et al., *J. Immunol.*, 157:1840 (1996); Klinman, et al., *J. Immunol.*, 158:3635 (1997); Sato, et al., *Science*, 273:352 (1996).

In particular, ISS useful in the invention include those that have hexameric nucleotide sequences having "CpG" motifs. Although DNA sequences are preferred, RNA ISS can be used, with inosine and/or uracil substitutions for nucleotides in the hexamer sequences.

10 For example, DNA based ISS useful in the invention include those that have the following hexameric nucleotide sequences:

AACGTT, AGCGTC, AGCGTT, GACGTT, GGCGTT, AACGTC, AGCGTC, GACGTC,  
15 GGCCTC, AACGCC, AGCGCC, GACGCC, GGCGCC, AGCGCT, GACGCT, GGCGCT,  
TTCGAA, GGCGTT, AACGCC, and GTCGTT (SEQ ID NOs: 5-24, respectively).

Also useful are octamers in the form of 5'-rrcgypyg-3' (SEQ ID NO: 3), such as AGCGTCCG, AACGTTCG, AGCGTTCG, GACGTTCG, GGCGTTCG, AACGTTCG, and AGCGTCCG  
20 (SEQ ID NOs: 25-31, respectively), and in the form of 5'-rycgypyg-3' (SEQ ID NO: 4), wherein the y is preferably "t", larger ISS-ODN having a second CG further 3' to the core hexamer sequence, and bacterial DNA, which are enriched with ISS.

The ISS may or may not include palindromic regions. If present, a palindrome may extend only to a CpG motif, if present, in the core hexamer sequence, or may encompass more of the hexamer sequence as well as flanking nucleotide sequences.

25 In addition, backbone phosphate group modifications (e.g., methylphosphonate, phosphorothioate, phosphoroamidate and phosphorodithioate internucleotide linkages) can confer anti-microbial activity on the ISS and enhance their stability *in vivo*, making them particularly useful in therapeutic applications. A particularly useful phosphate group modification is the conversion to the phosphorothioate or phosphorodithioate forms of ISS. In

addition to their potentially anti-microbial properties, phosphorothioates and phosphorodithioates are more resistant to degradation *in vivo* than their unmodified oligonucleotide counterparts, making the ISS of the invention more available to the subject.

- ISS can be synthesized using techniques and nucleic acid synthesis equipment that are well-known in the art. For reference in this regard, see, e.g., Ausubel, et al., Current Protocols in Molecular Biology, Chs. 2 and 4 (Wiley Interscience, 1989); Maniatis, et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. New York, 1982); U.S. Patent No. 4,458,066 and U.S. Patent No. 4,650,675. Because the ISS is non-coding, there is no concern about maintaining an open reading frame during synthesis.
- 10 Alternatively, ISS can be isolated from microbial species (especially mycobacteria) using techniques well-known in the art, such as nucleic acid hybridization. Whole or fragmented bacterial DNA can be used. Preferably, such isolated ISS will be purified to a substantially pure state; i.e., to be free of endogenous contaminants, such as lipopolysaccharides.

#### Compositions

- 15 The invention provides compositions that are useful for treating and preventing disease, such as allergy, cancer or infection. In one embodiment, the composition is a pharmaceutical composition. The composition is preferably an immunotherapeutic composition. The composition can comprise a therapeutically or prophylactically effective amount of an ISS of the invention, as described above. The composition can optionally include a carrier, such as a 20 pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.

#### Administration and Dosage

- 25 In a preferred embodiment of the method, the ISS is administered via a systemic or mucosal route, or directly into a specific tissue, such as the liver, bone marrow, or into the tumor in the case of cancer therapy. Examples of systemic routes include, but are not limited to, intradermal, intramuscular, subcutaneous and intravenous administration. Examples of mucosal routes include, but are not limited to, intranasal, intravaginal, intrarectal, intratracheal

- and ophthalmic administration. Mucosal routes, particularly intranasal, intratracheal and ophthalmic, are preferred for protection against natural exposure to environmental pathogens such as RSV, flu viruses and cold viruses or to allergens such as grass and ragweed pollens and house dust mites. The local activation of innate immunity by ISS will enhance the
- 5 protective effect against a subsequently encountered substance, such as an antigen, allergen or microbial agent.

Treatment includes prophylaxis and therapy. Prophylaxis or therapy can be accomplished by a single direct administration at a single time point or multiple time points. Administration can also be delivered to a single or to multiple sites.

- 10 The subject can be any vertebrate, but will preferably be a mammal. Mammals include human, bovine, equine, canine, feline, porcine, and ovine animals. If a mammal, the subject will preferably be a human, but may also be a domestic livestock, laboratory subject or pet animal.

The dose of ISS administrated to a subject, in the context of the present invention, should be sufficient to effect a beneficial therapeutic response in the subject over time, or to inhibit  
15 growth of cancer cells, to inhibit allergic responses or to inhibit infection. Thus, ISS is administered to a patient in an amount sufficient to elicit an effective immune response to the specific antigens and/or to alleviate, reduce, cure or at least partially arrest symptoms and/or complications from the disease or infection. An amount adequate to accomplish this is defined as a "therapeutically effective dose."

- 20 A particular advantage of the ISS of the invention is their capacity to exert immunomodulatory activity even at relatively minute dosages. Although the dosage used will vary depending on the clinical goals to be achieved, a suitable dosage range is one that provides up to about 1-1000 µg of ISS/ml of carrier in a single dosage. Alternatively, a target dosage of ISS can be considered to be about 1-10 µM in a sample of subject blood drawn within the first 24-48  
25 hours after administration of ISS. Based on current studies, ISS are believed to have little or no toxicity at these dosage levels.

In this respect, it should be noted that the anti-inflammatory (anti-allergenic), anti-microbial and immunotherapeutic activities of ISS in the invention are essentially dose-dependent. Therefore, to increase ISS potency by a magnitude of two, each single dose is doubled in

concentration. Clinically, it may be advisable to administer the ISS in a low dosage (e.g., about 1 µg/ml to about 50 µg/ml), then increase the dosage as needed to achieve the desired therapeutic goal. Some routes of administration, such as via ophthalmic drops, will require higher concentrations. Those skilled in the art can adjust the dosage and concentration to suit  
5 the particular route of delivery.

In view of the teaching provided by this disclosure, those of ordinary skill in the clinical arts will be familiar with, or can readily ascertain, suitable parameters for administration of ISS according to the invention.

### EXAMPLES

- 10 The following examples are presented to illustrate the present invention and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the invention.

#### Example 1: ISS Pre-Priming Elicits Extended Th1-Biased Immune Responses

This example demonstrates that ISS provide Th1 adjuvant activity for an extended period of time after delivery. ISS were administered intradermally (i.d.) up to 28 days prior to a primary i.d. immunization with β-galactosidase (β-gal), and enhanced antibody production, antigen-specific cytokine production and CTL response were measured.  
15

#### *Methods*

##### *Immunization reagents*

- 20 β-gal, lipopolysaccharide (LPS), and cholera toxin (CT) (Sigma, St Louis, MO), ISS-ODN and mutated phosphorothioate oligodeoxynucleotide (M-ODN) (Trilink Biotechnologies, San Diego, CA) were used to immunize mice. The ISS-ODN used in these studies has the following sequence: 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO: 32). The M-ODN has the sequence 5'-TGACTGTGAACCTTAGAGATGA-3' (SEQ ID NO: 33).

*Immunization protocols*

Female BALB/c mice, aged 6-8 weeks, were purchased from Jackson Laboratory (Bar Harbor, ME) and were used in all experiments. The i.d. and i.n. immunization protocols used in these experiments are outlined in Figure 1. In brief, ISS-ODN was delivered to mice from 5 28 days to 1 day prior to or with  $\beta$ -gal. Mice received a single i.d. injection with ISS (50  $\mu$ g) either the specified day before or with i.d.  $\beta$ -gal (50  $\mu$ g) immunization. Control mice received i.d.  $\beta$ -gal immunization alone or with M-ODN. Splenocytes were harvested from sacrificed mice during week 7. Intradermal injections were performed at the base of the tail in 50  $\mu$ l of saline. Mice were anaesthetized for i.n. delivery of reagents with Metophane (Mallinckrodt 10 Veterinary Inc., Mundelein, IL) and 15  $\mu$ l of saline with reagents was delivered to each nare. In some experiments 50  $\mu$ g of ISS-ODN, M-ODN, or LPS were injected i.d., and serum and, spleens were collected at times ranging from 1-14 days after injection to assess *in vivo* immune activation.

*Collection of samples*

15 Blood was obtained by retro-orbital bleed, serum was spun and then stored at -70 °C until IgG2a, IgG1, or IFN $\gamma$  assay.

*Antibody assays*

Serum was used in ELISA assays for antigen specific immunoglobulin as described previously. Results are expressed in units/ml (U/ml) based on pooled high titer anti- $\beta$ -gal standards 20 obtained from mice receiving multiple immunizations. The undiluted serum IgG standards were given an arbitrary concentration of 400,000 U/ml. Ninety-six-well plates were coated with 5  $\mu$ g of  $\beta$ -gal (Sigma) in 50  $\mu$ l borate buffered saline (BBS; pH 9.2) overnight at 4 °C. Plates were then incubated with 1%BSA in BBS for 2 hours at 37 °C. Plates were washed twice with BBS/0.5% Tween 20 (Sigma) and incubated with samples overnight at 4 °C. Plates 25 were washed 8 times with BBS/Tween 20 and incubated with alkaline phosphatase-linked anti-IgG1 or IgG2a (Southern Biotechnologies, Birmingham, AL) for 2 hours at room temperature. The plates were then washed 8 times with BBS/Tween 20 and incubated with a solution of p-nitrophenyl phosphate (1 mg/ml; Boehringer Mannheim). Absorbance at 405 nm

was read at 1 hour and compared to the standard curve on each plate using the DeltaSOFT II v. 3.66 program (Biometallics, Princeton, NJ).

*Cytokine assays*

Mouse spleens were harvested at week 8 for CTL and cytokine assays. Three days before 5 setting up cytokine assays mice were i.v. boosted with 10 µg β-gal. Mice were sacrificed by cervical dislocation. Spleens were harvested and teased to make single cell preparations.

Splenocyte cytokine profiles were analyzed by incubation of 5 X 10<sup>5</sup> splenocytes in 96-well plates in a final volume of 200 µl of supplemented RPMI 1640 with β-gal added at 10 µg/ml, at 37 °C/5% CO<sub>2</sub> as previously described. Culture supernatants were harvested at 72 hours and 10 analyzed by ELISA. Pharmagen (San Diego, CA) anti-IFNγ and anti-IL12 capture and detection antibodies, recombinant IFNγ and IL-12, were all used per the manufacturer's recommendations. A standard curve was generated on each plate using known amounts of recombinant IFNγ and each culture supernatant was compared to the standard curve on the plate using the DeltaSOFT II v. 3.66 program.

15 *CTL assays*

Seven million splenocytes from immunized mice were incubated with 6 X 10<sup>6</sup> mitomycin-C treated naive splenocytes in the presence of recombinant human IL-2 and class I H2<sup>d</sup> restricted β-gal nanopeptide (T-P-H-P-A-R-I-G-L; SEQ ID NO: 34), in supplemented RPMI 1640 with 10% FCS at 37 °C/5% CO<sub>2</sub>, as previously described. After 5 days, re-stimulated cells were 20 harvested and debris was removed by centrifugation on a lympholyte M (Accurate Chemicals, Westbury, NY) gradient. Specific lysis was measured by aliquotting effector cells with H2<sup>d</sup> restricted p815 peptide pulsed target cells at 25:1, 5:1, and 1:1 ratios. Controls for specific lysis included non-pulsed p815 cells, and p815 cells pulsed with an irrelevant influenza nucleoprotein peptide. Cells were incubated for 4 hours in clear 2% BSA supplemented RPMI 25 1640 in round bottom plates. Total and specific lysis were measured using the Promega Cytotox 96 kit (Madison, WI). The assay system measures lactate dehydrogenase (LDH) release using a substrate metabolized by LDH into a colored by-product. The equation used to calculate specific lysis was (target lysis – non-specific lysis)/(total lysis) X 100.

*Statistics*

Statistical analysis of results was conducted using Statview computer software (Abacus Concepts, Grand Rapids, MI). A two-tailed Student's t test was used to establish p values, and those having p values  $\leq 0.05$  were considered significant.

5    *Results*

Analysis of the IgG2a response of immunized mice demonstrated that ISS provides a prolonged window of adjuvant activity (Figure 2A). When compared to immunization with  $\beta$ -gal alone, mice receiving ISS up to 14 days prior to  $\beta$ -gal had a significant increase in their serum IgG2a response. Furthermore, the IgG2a response was improved over ISS/ $\beta$ -gal 10 co-immunization if ISS-ODN was given 3-7 days before antigen, and statistical significance was reached if ISS-ODN was delivered 7 days before antigen ( $p < 0.05$  for week 6 IgG2a levels) (Figure 2B). Of note, the relatively IL-4 dependent IgG1 response was not increased by ISS pre-priming or by co-delivery with  $\beta$ -gal (Figure 2C). Mice immunized with M-ODN either prior to or with  $\beta$ -gal immunization did not demonstrate an improved IgG2a or IgG1 15 response when compared to mice immunized with  $\beta$ -gal alone.

The effect of ISS pre-priming on cellular immune responses was next evaluated. Splenocytes were harvested from immunized mice during week 8, and utilized in both cytokine and CTL assays (Figures 3A-3C). Antigen specific IL-4 production was significantly increased in mice pre-primed up to 14 days before  $\beta$ -gal immunization compared to mice immunized with 20 antigen alone ( $p < 0.05$ ). In addition, mice ISS pre-primed 3-7 days before  $\beta$ -gal immunization demonstrated a 100% increase in their IFN $\gamma$  response compared to mice co-immunized with ISS and  $\beta$ -gal ( $p < 0.05$ ).

Further studies evaluated the CTL response of mice after ISS pre-priming. The results again demonstrate a prolonged window of ISS adjuvant activity. Delivery of ISS up to 14 days 25 before  $\beta$ -gal vaccination led to a significantly improved CTL response over  $\beta$ -gal vaccination without adjuvant ( $p < 0.05$ ). ISS pre-priming at day -7 and day -3 resulted in a trend toward improved response, but did not lead to a statistically significant increase in CTL activity when compared to ISS/ $\beta$ -gal co-immunization. Mice immunized with M-ODN either prior to or with

$\beta$ -gal immunization did not demonstrate an improved IFN $\gamma$  or CTL response when compared to mice immunized with  $\beta$ -gal alone.

The data presented in this example demonstrate that i.d. delivery of ISS, up to 2 weeks prior to i.d.  $\beta$ -gal administration, results in an improved Th1 biased immune response relative to i.d.

- 5 vaccination with antigen alone. Anti- $\beta$ -gal IgG2a (Th1 isotype), IFN $\gamma$  release by antigen specific T cells, and CTL activity against peptide pulsed target cells, are all higher in mice pre-primed (up to 14 days) with ISS compared to mice immunized with  $\beta$ -gal alone. The pre-priming effect was diminished when the interval between ISS and antigen delivery was extended to 28 days. Interestingly, the optimal immune response is seen in mice pre-primed  
10 with ISS 3-7 days prior to  $\beta$ -gal injection and not in mice co-delivered ISS and  $\beta$ -gal. A 3-7 day ISS pre-priming interval results in anti- $\beta$ -gal IgG2a levels and  $\beta$ -gal specific IFN $\gamma$  responses which are approximately twice as high as those seen in ISS/ $\beta$ -gal co-immunized mice.

Example 2: ISS Activate the Immune System For Up to 14 Days

- 15 This example demonstrates that serum levels of the type 1 cytokines IL-12 and IFN $\gamma$  are elevated for extended periods following injection of ISS into naïve mice. The data presented here show that the duration and peak expression of these intercellular signaling molecules correlate well with the duration and peak of the ISS pre-priming effect.

*Methods*

- 20 Serum levels of IL-12 and IFN $\gamma$  were measured in naïve mice before and 1-14 days after i.d. injection of ISS alone. The materials and assays used were the same as those described above in Example 1. In addition, the time course of peak *in vivo* splenocyte cytokine production after ISS delivery was evaluated using RT-PCR to measure IL-12 p40 and IFN $\gamma$  mRNA expression. Flow cytometry was used to measure the level of expression of various co-  
25 activation molecules on B cells from mice injected with ISS. The molecules examined include class I and II, CD40 and B7.2. To control for auto-fluorescence and non-specific antibody staining, isotype control antibodies were used.

Mice were i.d. injected with 50 µg of ISS on day 0. Control mice received LPS (50 µg) or nothing. At serial time points after injection, serum was obtained and cytokine levels were analyzed by ELISA.

#### *RT-PCR*

- 5 For cytokine mRNA analysis, total cellular RNA was extracted from splenocytes using the Stratagene RNA Isolation Kit, (San Diego, CA) and subjected to semi-quantitative RT-PCR. First-strand cDNA preparation and PCR amplification were performed using the SuperScript Preamplification system (GibcoBRL, Gaithersburg, MD) and Advan Taq Plus DNA Polymerase (Clontech, San Francisco, CA), respectively. The primer sequences used were:
- 10 IL-12p40 sense 5'GGGACATCATCAAACCAGACC-3' (SEQ ID NO: 35), and antisense 5'-GCCAACCAAGCAGAAGACAGC-3' (SEQ ID NO: 36); IFN $\gamma$  sense 5'-TGCATCTTGGCTTGAGCTTCATGGC-3' (SEQ ID NO: 37), and antisense 5'-TGGACCTGTGGTTGTTGACCTCAAACITGGC-3' (SEQ ID NO: 38); and GAPDH sense 5'- ACCACAGTCCATGCCATCAC-3' (SEQ ID NO: 39) and antisense, 15 5'-TCCACCACCTGTTGCTGTA-3' (SEQ ID NO: 40).

PCR products were visualized by electrophoresis on 2% agarose gels after staining with ethidium bromide.

#### *Flow Cytometry*

- At serial time points after injection, mice were sacrificed and spleens were harvested and made 20 into single cell suspensions. Cells were stained with B220 to identify B cells and with FITC labeled antibodies to detect co-stimulatory molecules identified in the Table 2. Live cells (propidium iodide-negative) were analyzed by flow cytometry (Becton Dickinson, San Jose, CA).

The flow cytometry methods used in this example have been described by Martin-Orozco E et 25 al., 1999, Enhancement of Antigen Presenting Cell Surface Molecules Involved in Cognate Interactions by Immunostimulatory DNA Sequences (ISS), *Int. Immunol.* 11 (in press). Briefly, following incubation with Fc block (PharMingen, San Diego, CA), sample cells were stained with PE conjugated antibodies specific for B cells (anti-B220, PharMingen) and with FITC conjugated antibodies specific for the following surface molecules: anti-MHC class 1,

class II, CD16/32, CD40, CD80, and CD86 (PharMingen). Isotype controls for the specific surface markers are as follows, Hamster IgG, Hamster IgM, Rat IgG2a, Rat IgG2b, Rat IgM, Mouse IgG2&, Mouse IgG2b (Cal Tag or PharMingen). Propidium iodide was included in the last wash at a concentration of 2 µg/ml. Live cells (propidium iodide-negative) were analyzed 5 on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). The data were analyzed with Cell Quest (Becton Dickinson) and FlowJo (Tree Star, San Carlos, CA) software.

Immunostimulatory oligodeoxynucleotide treatment significantly increased non-specific antibody binding or autofluorescence (seen as increases in isotype control antibody-stained mean fluorescence), so this was controlled for with the mean fluorescence intensity ratio 10 (MFIR; mean fluorescence when stained for surface molecule/mean fluorescence when stained with isotype control antibody). The MFIR represents the fold increase in surface marker expression relative to background autofluorescence and nonspecific antibody binding. MFIR provides a conservative and accurate estimate of expression of surface molecules when studying cells treated with ISS-containing DNA.

15 *Results*

Serum levels of cytokines measured in naïve mice before and 1-14 days after i.d. injection of ISS alone are shown in Table 1. The data presented in Table 1 represent means for 2 mice per group plus or minus the standard error of the mean. The results show that i.d. injection of ISS into mice leads to elevated serum IL-12 and IFN $\gamma$  levels for up to 2 weeks after delivery. 20 These results are consistent with the 14 day window of ISS adjuvant noted with the antigen specific immune response. However, peak serum levels of IL- 12 and IFN $\gamma$  were seen 1 day after ISS delivery and serum IgG2a levels and splenocyte cytokine and CTL responses were highest in mice pre-primed with ISS 3-7 days before  $\beta$ -gal immunization.

**Table 1: In vivo cytokine production induced by ISS-ODN**

ISS-ODN	IL-12 (pg/ml)	IFN $\gamma$ (pg/ml)
None	<42	<14
Day (1)	4028±1878	343±83
Day (3)	2356±464	312±101
Day (7)	2034±288	174±36
Day (14)	763±255	35±71
LPS Day 7	<42	<14

- Because many of the antigen specific immune responses which characterize the ISS pre-priming effect were measured in spleen, the time course of peak *in vivo* splenocyte cytokine production after ISS delivery was examined. Using RT-PCR, the time course for peak splenocyte IL12 p40 and IFN $\gamma$  mRNA expression was assessed. Intradermal ISS delivery led to peak levels of IL12 p40 and IFN $\gamma$  mRNA at 7 and 3 days, respectively (Figure 4). These time points fall within the window identified for the maximal ISS pre-priming effect on antigen specific immunity.
- Previous reports have shown that a number of co-activation molecules on B cells and APCs are up-regulated by ISS. The relatively long ISS pre-priming effect could be mediated by up-regulation of these surface proteins. Experiments were designed to establish if i.d. ISS injection would lead to a detectable and prolonged increase in the expression of these molecules *in vivo*. Flow cytometry was used to measure the level of expression of various co-activation molecules on B cells from ISS injected mice. To control for auto-fluorescence and non-specific antibody staining, isotype control antibodies were used and the results are presented as mean fluorescence intensity ratio (MFIR; MFI of antibody of interest/MFI of isotype control).
- As shown in Table 2, ISS increased the expression of a number of co-activation molecules such as class I and II, CD40, and B7.2 on the surface of B cells from ISS injected mice. The time course for up-regulation of these surface proteins was extended and peak co-stimulatory

molecule expression was seen 3-7 days after ISS injection. These results were consistent with the splenocyte cytokine RT-PCR results, and the 3-7 day interval between ISS pre-priming and  $\beta$ -gal vaccination which led to maximal antigen specific immunity.

**Table 2: Up-regulation of cell surface molecules *in vivo* by ISS-ODN**

ISS	H-2K <sup>d</sup>	I-A <sup>d</sup>	CD16/ CD32	CD40	CD54	CD80	CD86
	(MHC class I)	(MHC class II)			(ICAM-1)	(B7-1)	(B7.2)
None	25.3	77.9	7.26	11.4	4.5	2.85	1.75
Day 3	27.1	87.1	9.3	11.7	7.68	2.85	2.18
Day 7	27.7	118	8.23	12.4	7.98	2.64	2.12
Day 14	30.1	94.9	7.26	9.5	6.36	2.37	1.97

5

**Example 3: Mucosal ISS Pre-Priming Enhances Th1 and IgA Adjuvant Activity**

This example shows that other forms of immunity, e.g. mucosal immunity, can be enhanced by pre-priming with ISS. The example also shows that intranasal (i.n.) delivery of ISS can modulate both systemic and mucosal immune responses.

10 *Methods*

The materials and assays used were as described above in Example 1. Mice received a single i.n. injection with ISS (50  $\mu$ g) either the specified day before or with i.n.  $\beta$ -gal (50  $\mu$ g) immunization. Control mice received i.n.  $\beta$ -gal immunization alone or in conjunction with M-ODN. Splenocytes were harvested from sacrificed mice during week 7.

15 Bronchoalveolar lavage fluid (BALF) was used in ELISA assays for antigen specific immunoglobulin. Fecal IgA standards were given arbitrary concentrations of 20,000 U/ml. BALF was obtained by cannulation of the trachea of sacrificed mice during week 8. The lungs were then flushed with 0.8ml of PBS. The return was spun to remove cellular debris, and frozen at -70 °C until IgA assay.

*Results*

Table 3 and Figure 5 show that i.n. pre-priming provides a 7 day window of systemic Th1 and mucosal IgA adjuvant activity. This window of adjuvant activity is shorter than when reagents are delivered i.d. Nonetheless, all immune parameters were significantly higher if mice received 5 ISS within the week preceding or with  $\beta$ -gal than if mice were immunized with  $\beta$ -gal alone. Mice immunized with M-ODN either prior to or with  $\beta$ -gal immunization did not demonstrate an improved IFN $\gamma$  or CTL response when compared to mice immunized with  $\beta$ -gal alone. The pre-priming effect observed on the BALF IgA response was modest but prolonged (1 week). Recognizing that without adjuvant the immune response to simple protein antigens such as 10  $\beta$ -gal is negligible, the week long ISS pre-priming effect with i.n. delivery is significant.

Table 3: Anti- $\beta$ -gal Ig production induced by mucosal pre-priming and immunization

ISS-ODN	$\beta$ -gal	Serum IgG2a (U/ml)	BALF IgA (U/ml)
--	+	<500	<50
Day (0)	+	239000±71500	2940±825
Day(-1)	+	322000±112000	463±47
Day (-3)	+	38000±3490	398±38
Day (-7)	+	17800±4830	459±183
Day (-14)	+	<500	<50

A stronger i.n. ISS pre-priming effect was observed on the anti- $\beta$ -gal IgG2a levels, CTL activity and antigen specific IFN $\gamma$  responses. Immunostimulatory oligodeoxynucleotide pre-15 priming at day -1 improved the IgG2a response slightly and the antigen specific splenocyte IFN $\gamma$  response was improved significantly ( $p<0.05$ ) compared to i.n. co-immunization with ISS and  $\beta$ -gal. These results demonstrate that ISS pre-priming is also effective with mucosal delivery, although the duration and the optimal interval between ISS and  $\beta$ -gal delivery were different than with i.d. delivery.

*Discussion*

A previous epidemiological study conducted on approximately 1000 Japanese school children documented a correlation between exposure to Mycobacteria tuberculosis (MTB) and a Th1 biased serum cytokine profile in study subjects. In addition, purified protein derivative (PPD) converters demonstrated a significantly lower incidence of allergic disease, and significantly lower serum IgE levels versus PPD negative school children (Shirakawa, T. et al., 1997, Science 275:77-9). Similar observations were made in an experimental murine system (Erb, K. I. et al., 1998, J. Exp. Med. 187:561-9). In this respect, exposure to MTB may be considered to pre-prime the host toward Th1 immunity. Moreover, a recent study demonstrated that the infection of dendritic cells with MTB resulted in the release of TNF $\alpha$ , and IL-12, as well as the up-regulation of MHC class I, ICAM-1, CD40, and B7 co-stimulatory molecules (Henderson, R. A. et al., 1997, J. Immunol. 159:635). This activation profile is very similar to the pattern induced with ISS. As ISS DNA was initially identified and isolated from MTB DNA, it is conceivable that this adjuvant plays a role in biasing the immune profile of MTB exposed hosts toward a Th1 phenotype, as do synthetic ISS-ODNs as demonstrated herein.

In gene vaccinated animals, ISS (CpG motifs) within the plasmid DNA (pDNA) backbone generate the necessary initial cytokine milieu (i.e., IL-12 and IFNs) to foster a Th1 response to the encoded antigen. Thus, gene vaccination plasmids provide both a source of adjuvant and antigen. These two activities are probably not simultaneous. The local induction of cytokine by ISS DNA is rapid (within 24 hours) and probably precedes the expression of sufficient amounts of antigen to elicit an effective immune response. A similar argument can be made for the up-regulation of co-stimulatory ligands. Thus, in gene vaccination, the pre-priming effects mediated by ISS DNA are likely to contribute to the Th1 biased immune response to the encoded antigen.

The above examples show that pre-priming enhances a variety of immune responses and is effective for enhancing both mucosal and systemic immunity. In summary, the invention provides a novel paradigm for Th1 biased immunization, called ISS pre-priming. Immunostimulatory sequence DNA administration biases the host immune system toward Th1 biased immune responses for up to 2 weeks. In addition, ISS delivered up to 7 days before antigen produces a stronger immune response than ISS/antigen co-immunization.

The data presented herein show that ISS can not only be used as an adjuvant in the traditional sense, but that it can also be used as an immuno-modifying therapeutic agent. For example, ISS might be i.d. injected or applied i.n. for the treatment of allergic rhinitis or inhaled to treat asthma. This immunologic strategy would provide relatively prolonged Th1 biased

5 immunologic protection against continuous exposure to inhaled allergens. Instead of amplifying a pre-existing allergic Th2 biased immune response, allergen exposure would down-regulate allergic inflammation of the nasal mucosa and bronchial surface via the numerous type 1 cytokines released after ISS exposure. A similar approach might be effective for preventing or treating infectious diseases such as influenza or rotavirus gastroenteritis via a

10 Th1 biased and activated immune system post ISS pre-priming. This invention provides ISS pre-priming as a new vaccination strategy, and a new paradigm for the prevention and treatment of infectious, allergic and malignant disease.

Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.

CLAIMS

What is claimed is:

1. A method for enhancing an immune response to a substance comprising administering an immunostimulatory nucleotide sequence (ISS) to a subject at least one hour prior to exposure to the substance by the subject.  
5
2. The method of claim 1, wherein the immune response is innate immunity.
3. The method of claim 1, wherein the immune response is a Th1 response.
4. The method of claim 1, wherein the immune response includes production of an antibody.  
10
5. The method of claim 4, wherein the antibody is of the IgG2 class.
6. The method of claim 1, wherein the immune response includes release of antigen-specific interferon- $\gamma$ .
7. The method of claim 1, wherein the immune response includes a cytotoxic T lymphocyte (CTL) response.  
15
8. The method of claim 1, wherein the substance is an antigen or pathogen associated with an infectious disease, an allergen or a cancer.  
10
9. The method of claim 8, wherein the infectious disease is selected from the group comprising viral, bacterial, mycobacterial and parasitic disease.  
20
10. The method of claim 1, wherein the ISS comprises a CG, p(GC) or p(IC) DNA or RNA nucleotide sequence.  
11. The method of claim 1, wherein the ISS comprises the sequence 5'-rrcggy-3' (SEQ ID NO: 1), 5'-rycggy-3' (SEQ ID NO: 2), 5'-rrcggycg-3' (SEQ ID NO: 3) or 5'-rycggycg-3' (SEQ ID NO: 4).

12. The method of claim 11, wherein the nucleotide sequence is selected from a group comprising AACGTT (SEQ ID NO: 5), AGCGTC (SEQ ID NO: 6), AGCGTT (SEQ ID NO: 7), GACGTT (SEQ ID NO: 8), GGCGTT (SEQ ID NO: 9), AACGTT (SEQ ID NO: 10), GTCGTT (SEQ ID NO: 24), AGCGTCCG (SEQ ID NO: 25),  
5 AACGTTCG (SEQ ID NO: 26), AGCGTTCG (SEQ ID NO: 27), GACGTTCG (SEQ ID NO: 28), GGCGTTCG (SEQ ID NO: 29), AACGTTCG (SEQ ID NO: 30), and AGCGTCCG (SEQ ID NO: 31).
13. The method of claim 1, wherein the ISS is administered between about 6 hours and about 6 weeks prior to antigen administration.
- 10 14. The method of claim 1, wherein the ISS is administered between about 1 day and about 4 weeks prior to antigen administration.
15. The method of claim 1, wherein the ISS is administered between about 3 days and about 8 days prior to antigen administration.
16. The method of claim 1, wherein the ISS is administered via a mucosal or systemic route.  
15
17. The method of claim 16, wherein the mucosal route is intranasal, ophthalmic, intratracheal, intravaginal or intrarectal.
18. The method of claim 16, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.
- 20 19. A method of immunizing a subject against a substance comprising administering to the subject an ISS at least one hour prior to exposing the subject to the substance.
20. The method of claim 19, wherein the ISS comprises a CG, p(GC) or p(IC) DNA or RNA nucleotide sequence.
21. The method of claim 19, wherein the ISS comprises the sequence 5'-rrcggy-3' (SEQ ID NO: 1), 5'-rycggy-3' (SEQ ID NO: 2), 5'-rrcggycg-3' (SEQ ID NO: 3) or 5'-rycggycg-  
25 3' (SEQ ID NO: 4).

22. The method of claim 21, wherein the nucleotide sequence is selected from a group comprising AACGTT (SEQ ID NO: 5), AGCGTC (SEQ ID NO: 6), AGCGTT (SEQ ID NO: 7), GACGTT (SEQ ID NO: 8), GGCGTT (SEQ ID NO: 9), AACGTT (SEQ ID NO: 10), GTCGTT (SEQ ID NO: 24), AGCGTCCG (SEQ ID NO: 25),  
5 AACGTTCG (SEQ ID NO: 26), AGCGTTCG (SEQ ID NO: 27), GACGTTCG (SEQ ID NO: 28), GGCGTTCG (SEQ ID NO: 29), AACGTTCG (SEQ ID NO: 30), and AGCGTCCG (SEQ ID NO: 31).
23. The method of claim 19, wherein the ISS is administered between about 6 hours and about 6 weeks prior to exposure to the substance.
- 10 24. The method of claim 19, wherein the ISS is administered between about 1 day and about 4 weeks prior to exposure to the substance.
25. The method of claim 19, wherein the ISS is administered between about 3 days and about 8 days prior to exposure to the substance.
- 15 26. The method of claim 19, wherein the substance is an antigen or pathogen associated with an infectious disease, an allergen or a cancer.
27. The method of claim 26, wherein the infectious disease is selected from the group comprising viral, bacterial, mycobacterial and parasitic disease.
28. The method of claim 19, wherein the ISS is administered via a mucosal or systemic route.
- 20 29. The method of claim 28, wherein the mucosal route is intranasal, ophthalmic, intratracheal, intravaginal or intrarectal.
30. The method of claim 28, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.
- 25 31. A method of eliciting IgG2 antibody production comprising administering to a subject an ISS at least one hour prior to administration of an antigen to the subject.

32. The method of claim 31, wherein the ISS comprises a CG, p(GC) or p(IC) DNA or RNA nucleotide sequence.
33. The method of claim 31, wherein the ISS comprises the sequence 5'-rrcgyy-3' (SEQ ID NO: 1), 5'-rycgyy-3' (SEQ ID NO: 2), 5'-rrcgyycg-3' (SEQ ID NO: 3) or 5'-rycgyycg-3' (SEQ ID NO: 4).
34. The method of claim 33, wherein the nucleotide sequence is selected from a group comprising AACGTT (SEQ ID NO: 5), AGCGTC (SEQ ID NO: 6), AGCGTT (SEQ ID NO: 7), GACGTT (SEQ ID NO: 8), GGCGTT (SEQ ID NO: 9), AACGTC (SEQ ID NO: 10), GTCGTT (SEQ ID NO: 24), AGCGTCCG (SEQ ID NO: 25), AACGTTCG (SEQ ID NO: 26), AGCGTTCG (SEQ ID NO: 27), GACGTTCG (SEQ ID NO: 28), GGCGTTCG (SEQ ID NO: 29), AACGTTCG (SEQ ID NO: 30), and AGCGTCCG (SEQ ID NO: 31).
35. The method of claim 31, wherein the ISS is administered between about 6 hours and about 6 weeks prior to antigen administration.
36. The method of claim 31, wherein the ISS is administered between about 1 day and about 4 weeks prior to antigen administration.
37. The method of claim 31, wherein the ISS is administered between about 3 days and about 8 days prior to antigen administration.
38. The method of claim 31, wherein the antigen is associated with an infectious disease, an allergen or a cancer.
39. The method of claim 38, wherein the infectious disease is selected from the group comprising viral, bacterial, mycobacterial and parasitic disease.
40. The method of claim 31, wherein the ISS is administered via a mucosal or systemic route.
41. The method of claim 40, wherein the mucosal route is intranasal, ophthalmic, intratracheal, intravaginal or intrarectal.

42. The method of claim 40, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.




FIG. 1

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B





FIG. 3C



4/5




FIG. 4

FIG. 5A





FIG. 5B



## SEQUENCE LISTING

<110> Raz, Eyal  
Kobayashi, Hiroko

<120> Method for Enhancing an Immune Response

<130> 6510-189WO1

<150> 09/347,343  
<151> 1999-07-02

<160> 40

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 1  
rrcgYY

6

<210> 2  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 2  
rycgYY

6

<210> 3  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 3  
rrcgyycg

8

<210> 4  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 4  
rycgyycg

8

<210> 5  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 5  
aacgtt

6

<210> 6  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 6  
agcgtc

6

<210> 7  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 7  
agcgtt

6

<210> 8  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 8  
gacgtt

6

<210> 9  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 9

ggcggtt

6

<210> 10

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 10

aacgtc

6

<210> 11

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 11

agcgtc

6

<210> 12

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 12

gacgtc

6

<210> 13

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 13

ggcgtc

6

<210> 14

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 14  
aacgcc  
  
<210> 15  
<211> 6  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide  
  
<400> 15  
agcgcc  
  
<210> 16  
<211> 6  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide  
)  
  
<400> 16  
gacgcc  
  
<210> 17  
<211> 6  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide  
  
<400> 17  
ggcgcc  
  
<210> 18  
<211> 6  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide  
  
<400> 18  
agcgct  
  
<210> 19  
<211> 6  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide  
  
<400> 19

6

6

6

6

6

gacgct  
6

<210> 20  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 20  
ggcgct  
6

<210> 21  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 21  
ttcgaa  
6

<210> 22  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 22  
ggcggt  
6

<210> 23  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 23  
aacgcc  
6

<210> 24  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 24  
gtcggt  
6

<210> 25  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 25  
agcgtccg

<210> 26  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 26  
aacgttcg

<210> 27  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 27  
agcgttcg

<210> 28  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 28  
gacgttcg

<210> 29  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 29  
ggcggttcg

<210> 30

8

8

8

8

8

<211> 8  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide

<400> 30  
aacgttcg  
  
<210> 31  
<211> 8  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide

<400> 31  
agcgtccg  
  
<210> 32  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide

<400> 32  
tgactgtgaa cgttcgagat ga  
  
<210> 33  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic oligonucleotide

<400> 33  
tgactgtgaa ccttagagat ga  
  
<210> 34  
<211> 9  
<212> PRT  
<213> Escherichia coli

<400> 34  
Thr Pro His Pro Ala Arg Ile Gly Leu  
1 5

<210> 35  
<211> 21  
<212> DNA  
<213> Artificial Sequence

8

8

22

22

<220>  
<223> Synthetic oligonucleotide

<400> 35  
gggacatcat caaaccagac c

21

<210> 36  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 36  
gccaaaccaag cagaagacag c

21

<210> 37  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 37  
tgcatcttgg ctttgagct cttccatg gc

32

<210> 38  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 38  
tggacctgtg ggttgttgc ac tc aa act tg gc

32

<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 39  
accacagtcc atgccatcac

20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

**WO 01/02007**

**PCT/US00/18229**

**<223> Synthetic oligonucleotide**

**<400> 40**

**tccaccaccc tggcgctgta**

**20**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/18229

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) A61K 39/00, 39/02, 45/00; C07H 21/04  
 US CL : 424/184.1, 234.1, 278.1, 282.1; 514/44; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 234.1, 278.1, 282.1; 514/44; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, CAPLUS, WEST2.0, GENCORE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BROIDE et al. DNA-Based immunization for asthma. International Archives of Allergy and Immunology. February 1999, Vol. 118, No. 2-4, pages 453-6, see entire article.	1-3, 7-10, 13-20, 23-32, 35-42
X,P	KOBAYASHI et al. Immunostimulatory DNA prepriming: A novel approach for prolonged Th1-biased immunity. Cellular Immunology. 25 November 1999, Vol. 198, No. 1, pages 69-75, see entire article.	1-3, 7-10, 13-20, 23-32, 35-42
X	SPIEGELBERG et al. Inhibition of allergic inflammation in the lung by plasmid DNA allergen immunization. Pediatric Pulmonology. Supplement. 1999, Vol. 18, pages 118-121, especially abstract.	1-3, 7-10, 13-20, 23-32, 35-42

Further documents are listed in the continuation of Box C.  See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• "A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• "E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
• "O" document referring to an oral disclosure, use, exhibition or other means		
• "P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
29 AUGUST 2000	13 OCT 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Dorothy Lawrence</i> <i>for</i> CARRIE MARLENE STROUP
Facsimile No. (703) 305-3230	Telephone No. (703) 306-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/18229

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHU et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. Journal of Experimental Medicine. 17 November 1997, Vol. 186, No. 10, pages 1623-1631, especially abstract.	1-42
A	WEINER et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proceedings of the National Academy of Sciences USA. 30 September 1997, Vol. 94, No. 20, pages 10833-10837, especially abstract.	1-42

**THIS PAGE BLANK (USPTO)**